Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)

Part of paid clinical trials in Los Angeles, California.

Sponsor
Cedars-Sinai Medical Center
Study ID
NCT06988150
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.

Key Dates

Start date
Apr 14, 2025
Status verified
May 2025
Primary completion
Apr 14, 2026
Completion
Apr 14, 2026

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Pancreatic adenocarcinoma with clinically significant weight loss.
    Patients diagnosed with pancreatic adenocarcinoma with clinically significant weight loss.

Primary Outcome Measure

SIBO in PDAC [ Time Frame: At Screening Visit ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cedars-Sinai Medical CenterLos AngelesCalifornia90048
Abrahm Levi
[email protected]
310-248-8084
Andrew E. Hendifar, M.D., M.P.H. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Cedars-Sinai Medical Center· Los Angeles, CA

Related Studies